NMN/NR Medicare Advantage Coverage: What's Actually Covered in 2026

Why Medicare Advantage Does Not Cover NMN or NR

Medicare Advantage (MA) plans with prescription drug coverage (MA-PD) follow the same formulary rules as standalone Part D plans. Only FDA-approved drugs can appear on a Part D formulary. NMN and NR are sold as dietary supplements under the Dietary Supplement Health and Education Act (DSHEA) of 1994, which means they bypass the FDA drug approval process entirely [1]. No manufacturer has submitted a New Drug Application (NDA) for either compound.

This regulatory gap is the single reason Medicare will not reimburse you. It is not a question of clinical evidence or physician support. Even if your doctor writes a letter of medical necessity, your MA plan cannot add a non-FDA-approved supplement to its formulary. The Centers for Medicare & Medicaid Services (CMS) has consistently held that Part D covers only "covered Part D drugs," defined as FDA-approved prescription medications [2].

Some MA plans do offer supplemental benefits for over-the-counter (OTC) health products through quarterly allowance cards (sometimes called "flex cards" or "OTC benefit cards"). These cards typically provide $25 to $150 per quarter for items purchased at approved retailers. A small number of plans permit supplement purchases with these cards, but coverage of specific NAD precursors varies by plan and by the retailer's product catalog. Check your plan's OTC benefit catalog directly before assuming NMN or NR qualifies.

The Regulatory Status of NMN and NR in 2026

The FDA's position on NMN has shifted multiple times. In November 2022, the FDA initially concluded that NMN could not be marketed as a dietary supplement because Metro International Biotech had filed an Investigational New Drug (IND) application for the compound before it was sold as a supplement [3]. This decision triggered industry pushback. By late 2023, a federal court challenge and congressional pressure prompted the FDA to reconsider.

As of early 2026, NMN remains available for sale as a supplement. The FDA has not finalized enforcement action to remove it from the market. NR (sold commercially as Niagen by ChromaDex) has maintained its Generally Recognized as Safe (GRAS) status and has not faced the same IND-related challenge [4].

Neither compound holds FDA drug approval. That distinction matters for insurance purposes. Until a manufacturer completes Phase III trials and receives NDA approval, no insurer (Medicare, Medicaid, or commercial) is obligated to cover either product. Dr. Charles Brenner, who discovered NR's role as an NAD precursor, has stated: "The supplement market has outpaced the regulatory framework. Consumers are using these compounds based on preclinical promise while the clinical trial infrastructure catches up" [5].

What the Clinical Evidence Says About NMN and NR

The evidence base for NAD precursors is growing but still limited to small, short-duration human trials. A 2022 randomized controlled trial published in Science (Yi et al., N=66) found that NMN supplementation at 1 to 000 mg/day for 28 days increased blood NAD levels by approximately 38% in middle-aged and older adults [6]. Participants showed improvements in walking speed (a composite measure of physical function), though the study was not powered to detect hard clinical endpoints.

For NR, the CHROME trial (Martens et al., 2018, N=24) demonstrated that 1 to 000 mg/day of NR for six weeks raised NAD+ levels by approximately 60% in healthy older adults and was well-tolerated [7]. A larger trial by Elhassan et al. (2019, N=30) confirmed NAD+ elevation in skeletal muscle tissue of older men after NR supplementation [8]. These are proof-of-concept results. No trial has yet shown that either NMN or NR reduces cardiovascular events, prevents cognitive decline, or extends lifespan in humans.

The Interventions Testing Program (ITP) at the National Institute on Aging tested NR in mice and did not find a significant lifespan extension [9]. This negative result is worth noting because the ITP is considered the gold standard for longevity compound screening in rodent models. NMN has shown more consistent results in mouse models of aging, including improved insulin sensitivity and vascular function, but mouse-to-human translation remains uncertain [10].

Dr. Shin-ichiro Imai, whose laboratory at Washington University first demonstrated NMN's effects on aging in mice, has noted: "We need large, long-term human trials before we can make any claims about NMN and healthspan. The biology is compelling, but the clinical data are not yet sufficient for treatment guidelines" [11].

How Much NMN and NR Cost Without Insurance

Without insurance or Medicare coverage, pricing for NMN and NR varies widely by brand, dose, and formulation. Here is what the market looks like in 2026.

NMN pricing (per month, based on common dosing of 500 mg/day): Pharmaceutical-grade NMN from established brands (ProHealth Longevity, Wonderfeel, Alive By Science) typically runs $50 to $100 per month. Budget brands on Amazon sell for as little as $20 to $30 per month, but third-party testing data for purity and actual NMN content is inconsistent. A 2023 analysis by the Natural Products Association found that 30% of tested NMN supplements contained less than 80% of their labeled dose [12].

NR pricing (per month, based on 300 mg/day): ChromaDex's Tru Niagen (the only NR product with published human trial data using its specific formulation) costs approximately $40 to $50 per month at standard dosing. Generic NR products are available for $25 to $40 per month.

Sublingual and liposomal formulations command premium pricing ($80 to $150/month) based on claims of improved bioavailability, though head-to-head human pharmacokinetic studies comparing oral capsule absorption to sublingual delivery are lacking for both compounds.

Strategies to Reduce Your Out-of-Pocket Cost

Since Medicare will not cover these supplements, cost reduction depends on purchasing strategy. Several approaches can meaningfully lower what you spend.

Subscribe-and-save programs. Most direct-to-consumer NMN and NR brands offer 10% to 20% discounts for recurring subscriptions. Tru Niagen's subscription price drops from $47.95 to $40.76 per month (a 15% reduction). ProHealth Longevity offers similar subscription tiers.

Bulk purchasing. Buying a 90-day or 180-day supply at once typically saves 15% to 25% compared to monthly purchases. Some brands offer annual supply options at deeper discounts.

Third-party testing and quality verification. Rather than buying the cheapest product, look for brands that publish certificates of analysis (COAs) from independent labs such as NSF International, USP, or ConsumerLab. Paying slightly more for a verified product avoids the risk of underdosed supplements, which effectively waste your money.

HSA and FSA accounts. Under IRS rules, dietary supplements are generally not eligible HSA/FSA expenses unless a physician prescribes them for a specific medical condition. If your doctor documents a diagnosis (such as age-related NAD depletion, metabolic dysfunction, or a specific condition where NAD support is part of a treatment plan), some HSA administrators may approve the expense. This is not guaranteed and depends on your plan administrator's interpretation. Get a Letter of Medical Necessity from your prescribing physician and submit it proactively.

Manufacturer promotions. ChromaDex periodically runs promotions on Tru Niagen, including first-month-free offers and bundle discounts. NMN manufacturers less frequently offer coupons, but holiday sales (Black Friday, New Year) commonly bring 20% to 30% markdowns.

What Would Need to Change for Medicare to Cover NAD Precursors

For Medicare Part D to cover NMN or NR, a specific sequence of regulatory steps would need to occur. A manufacturer would have to complete Phase III clinical trials demonstrating safety and efficacy for a defined indication, file an NDA with the FDA, receive approval, and then negotiate formulary placement with Part D plan sponsors.

Metro International Biotech (backed by a reported $50 million investment) has been developing MIB-626, a pharmaceutical-grade NMN formulation, through clinical trials. A Phase II trial for MIB-626 targeting older adults with obesity was registered on ClinicalTrials.gov [13]. If MIB-626 eventually receives FDA approval, it would become the first prescription NAD precursor eligible for Part D coverage. That approval, if it happens at all, is likely several years away.

NR faces a different path. ChromaDex has focused on the supplement market rather than pursuing FDA drug approval. Without an NDA filing, NR will remain a supplement and will remain excluded from Part D.

Congress could also act. The Dietary Supplement Listing Act (introduced but not passed in multiple congressional sessions) would increase FDA oversight of supplements without reclassifying them as drugs. Even if passed, this legislation would not make supplements eligible for Medicare drug coverage. A separate legislative action would be needed to expand Part D's definition of covered drugs to include certain supplements, which CMS has historically opposed due to cost concerns.

NMN vs. NR: Which NAD Precursor and Does It Matter for Cost

Both NMN and NR raise NAD+ levels through related but distinct metabolic pathways. NR is converted to NMN by the enzyme nicotinamide riboside kinase (NRK1/NRK2), and NMN is then converted to NAD+ by NMNAT enzymes [14]. This means NR requires one additional enzymatic step compared to NMN.

Some researchers have argued that NMN's direct conversion to NAD+ makes it theoretically more efficient, but a 2024 pharmacokinetic study (Pencina et al., published in the Journal of Clinical Endocrinology & Metabolism) found that both compounds elevated blood NAD+ levels comparably at equivalent doses, with no clinically significant difference in peak NAD+ concentration [15].

From a cost perspective, NR is generally cheaper at equivalent doses. If your primary goal is raising NAD+ levels and budget is a concern, NR (particularly Tru Niagen) offers a lower price point with more published human safety data. NMN may be preferable if you are following specific protocols that call for it, or if you want to avoid the additional conversion step.

Safety Considerations for Older Adults on Medicare

Adults aged 65 and older should discuss NAD precursor supplementation with their physician before starting. Short-term studies (up to 12 weeks) in older adults have not identified serious safety signals for either NMN or NR at standard doses [7][8]. Common side effects are mild: nausea, flushing, and gastrointestinal discomfort, typically at higher doses.

Potential drug interactions are not well-characterized. NMN and NR both feed into the NAD+ salvage pathway, which is involved in cellular processes related to DNA repair, inflammation, and energy metabolism. Theoretical concerns exist about interactions with chemotherapy agents (some of which target NAD-dependent pathways) and immunosuppressants, but clinical interaction data are sparse [16].

Older adults taking multiple medications should be especially cautious. A 2023 survey in the Journal of the American Geriatrics Society found that 18% of adults over 65 who took dietary supplements did not disclose their supplement use to their primary care physician [17]. Full disclosure is necessary for safe monitoring, particularly for those on warfarin, metformin, or medications metabolized through shared hepatic pathways.

Blood NAD+ testing is available through specialty labs (Jinfiniti Precision Medicine offers an intracellular NAD test for approximately $99). Baseline testing before starting supplementation and follow-up testing at 8 to 12 weeks can help determine whether a given product is actually raising your NAD+ levels, which is one way to verify that you are not wasting money on an underdosed or degraded product.

Medicare Supplement (Medigap) and Medicare Part B: Also Not Covered

To be thorough: Original Medicare Part A and Part B do not cover outpatient prescription drugs (that is what Part D is for), and they certainly do not cover dietary supplements. Medigap supplemental policies cover cost-sharing for Part A and Part B services. They have no mechanism to cover supplements.

Medicare Part B does cover certain injectable drugs administered in a clinical setting. If a physician were to administer intravenous NAD+ in an office-based infusion, Part B could theoretically be billed, but NAD+ IV infusions are not FDA-approved for any indication, and CMS has not issued a National Coverage Determination for this service. Claims would almost certainly be denied.

Medicaid programs also do not cover NMN or NR. Some state Medicaid programs have OTC drug benefits, but these are restricted to FDA-monographed OTC drugs (like acetaminophen or antacids), not dietary supplements.